ストックスクリーナーアプリを入手
96.22
0.83%
0.705
前日終値:
$95.52
開ける：
$96.54
24時間の取引高:
461.58K
Relative Volume:
0.14
時価総額：
$19.03B
収益：
$742.00K
当期純損益:
$-1.13B
株価収益率:
-16.26
EPS:
-5.9165
ネットキャッシュフロー:
$-913.73M
1週間 パフォーマンス:
-1.83%
1か月 パフォーマンス:
-6.71%
6か月 パフォーマンス:
+126.56%
1年 パフォーマンス:
+150.48%
1日の値動き範囲:
$94.29
$96.54
1週間の範囲:
$94.29
$100.08
52週間の値動き範囲:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
名前
Revolution Medicines Inc
セクター
電話
650-481-6801
住所
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
96.03 | 18.93B | 742.00K | -1.13B | -913.73M | -5.9165 |
VRTX
Vertex Pharmaceuticals Inc
|
453.71 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.84 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
693.27 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.30 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.39 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-02-27 | 再開されました | UBS | Buy |
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-11-03 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-09-12 | 再開されました | Raymond James | Strong Buy |
| 2025-09-05 | 開始されました | Truist | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-08-15 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2024-07-16 | 繰り返されました | Needham | Buy |
| 2024-07-12 | 開始されました | Barclays | Overweight |
| 2024-07-08 | 開始されました | Jefferies | Buy |
| 2024-04-12 | 繰り返されました | Needham | Buy |
| 2024-04-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-04 | 開始されました | Wedbush | Outperform |
| 2023-11-16 | 開始されました | Raymond James | Outperform |
| 2023-02-28 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-10-21 | 開始されました | Oppenheimer | Outperform |
| 2022-05-20 | 開始されました | BofA Securities | Neutral |
| 2022-03-01 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-08-12 | ダウングレード | Goldman | Buy → Neutral |
| 2021-05-18 | 開始されました | Goldman | Buy |
| 2020-05-21 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-09 | 開始されました | Cowen | Outperform |
| 2020-03-09 | 開始されました | Guggenheim | Buy |
| 2020-03-09 | 開始されました | JP Morgan | Neutral |
すべてを表示
Revolution Medicines Inc (RVMD) 最新ニュース
Wedbush Reiterates Revolution Medicines (RVMD) Outperform Recommendation - MSN
(RVMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating - MSN
A Look At Revolution Medicines (RVMD) Valuation After AACR RAS(ON) Pipeline Data Catalyst - simplywall.st
Revolution Medicines COO Horn sells $455,918 in shares By Investing.com - Investing.com South Africa
Revolution Medicines Eyes Guidance with Mixed Signals from Financial Reports - timothysykes.com
Revolution Medicines rises on daraxonrasib data that supports phase 3 program - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Revolution Medicines Insider Sold Shares Worth $455,919, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines Insider Sold Shares Worth $1,280,412, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines Insider Sold Shares Worth $427,965, According to a Recent SEC Filing - marketscreener.com
Wang Xiaolin, evp at Revolution Medicines, sells $199k in RVMD - Investing.com
Anders, Revolution Medicines CFO, sells $273k in RVMD stock - Investing.com
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,010 Shares of Stock - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Insider Sells 2,073 Shares - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 12,871 Shares - MarketBeat
Cislini, Revolution Medicines general counsel, sells $291,889 in RVMD stock By Investing.com - Investing.com India
Cislini, Revolution Medicines general counsel, sells $291,889 in RVMD stock - Investing.com
Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 2,753 Shares of Stock - MarketBeat
Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells 4,583 Shares of Stock - MarketBeat
Wang Xiaolin, evp at Revolution Medicines, sells $199k in RVMD By Investing.com - Investing.com India
Revolution Medicines exec Kelsey sells $427,964 in stock By Investing.com - Investing.com India
Anders, Revolution Medicines CFO, sells $273k in RVMD stock By Investing.com - Investing.com India
Revolution Medicines CEO Goldsmith sells $1.28 million in stock - Investing.com
Revolution Medicines exec Kelsey sells $427,964 in stock - Investing.com
Revolution Medicines COO Horn sells $455,918 in shares - Investing.com
Revolution Medicines CEO Goldsmith sells $1.28 million in stock By Investing.com - Investing.com Australia
Wei Lin, chief medical officer, sells $206k in Revolution Medicines - Investing.com
Revolution Medicines (NASDAQ: RVMD) CMO sells 2,073 shares for tax withholding - Stock Titan
Revolution Medicines (RVMD) officer sells 4,302 shares under 10b5-1 plan - Stock Titan
Revolution Medicines (RVMD) director sells 12,871 shares in 10b5-1 trade - Stock Titan
Revolution Medicines (RVMD) COO pre-planned sale tied to RSU tax - Stock Titan
CFO of Revolution Medicines (NASDAQ: RVMD) sells 2,753 shares - Stock Titan
Revolution Medicines (RVMD) counsel sells 2,958 pre-planned shares - Stock Titan
Revolution Medicines (RVMD) insider sale under 10b5-1 plan for RSU taxes - Stock Titan
Morgan Stanley schedules sale of RVMD (NASDAQ: RVMD) RSUs, prior insider sales listed - Stock Titan
Revolution Medicines (RVMD) Among Top Biotech M&A Targets - GuruFocus
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech - Seeking Alpha
Revolution Medicines, Inc. (RVMD) net loss widens amid progress on clinical trial programs - MSN
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
Stifel Reiterates Revolution Medicines (RVMD) Buy Recommendation - MSN
Wells Fargo Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
Revolution Medicines Secures $2 Billion Flexible Financing Deal with Royalty Pharma - MSN
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Bitget
Revolution Medicines Showcases RAS(ON) Inhibitor Pipeline Advances at AACR Annual Meeting 2026 - Quiver Quantitative
Revolution Medicines to Showcase Progress Across RAS(ON) - GlobeNewswire
Revolution Medicines brings lung and pancreatic cancer trial data to AACR 2026 - Stock Titan
Algert Global LLC Boosts Position in Revolution Medicines, Inc. $RVMD - MarketBeat
RVMD: Jefferies Raises Price Target for Revolution Medicines to $140 | RVMD Stock News - GuruFocus
RVMD SEC FilingsRevolution Medicines, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Revolution Medicines Inc (RVMD) 財務データ
収益
当期純利益
現金流量
EPS
1.56%
大文字化:
|
ボリューム (24 時間):